Walk the exhibit hall at any revenue cycle conference in 2026 and you’ll see the same word on nearly every booth banner: “agentic.” Ask ten vendors what their AI actually does, and you’ll get ten different answers — some accurate, some aspirational, and a few that sound like they were written by the AI itself. So is artificial intelligence really reshaping medical billing this year, or is most of it still marketing gloss on top of the same claim scrubbers billing teams have used for a decade? The honest answer is: both, depending on which corner of the revenue cycle you’re standing in.
Where the change is real
Strip away the buzzwords and there are several places where AI-driven tools have moved from pilot projects to production workflows at a meaningful number of practices and health systems:
- Claim scrubbing and coding suggestions. Machine-learning models trained on historical claims data are genuinely better than static rules engines at flagging combinations likely to trigger a payer edit or denial before the claim ever goes out.
- Denial prediction and triage. Instead of every denial landing in the same queue, predictive models score claims for denial risk pre-submission and route post-denial work by dollar value and win probability, so staff spend time on the appeals most likely to pay off.
- Eligibility and benefits verification. AI-assisted tools now combine standard 270/271 eligibility transactions with automated payer-portal lookups to fill in gaps that the EDI response alone often misses, such as specific benefit accumulators.
- Prior authorization drafting. Generative AI is increasingly used to pre-populate prior auth requests and appeal letters with the relevant clinical documentation and payer policy language, cutting the time a human spends starting from a blank page.
- Patient-facing automation. Chat-based tools and automated payment plan negotiators are handling a growing share of routine billing questions and self-service payments, freeing staff for calls that actually need a person.
Trade press coverage in 2026 has tracked this shift closely — see, for instance, TechTarget’s reporting on the gap between “agentic AI” hype and revenue cycle reality, and Medical Economics’ look at where AI billing claims hold up versus where they don’t. The throughline in nearly all of that coverage is the same: the underlying machine learning and natural language processing techniques are not new, but 2026 is the year they became reliably good enough, and cheap enough to deploy, that mid-sized practices — not just large health systems with data science teams — are running them in production.
Where it’s still mostly marketing
The gap between vendor claims and delivered reality tends to show up in three specific places.
“Fully autonomous” claims
No credible RCM vendor is running a fully hands-off claims process end to end for a diverse payer mix. What’s actually happening is automation of the routine 80% of claims — the ones that are clean, in-network, and well-documented — with human review still required for the exceptions, appeals involving clinical judgment, and anything with compliance exposure. “Autonomous” in a sales deck often means “we handle the easy cases without a human touching them,” which is a real and valuable thing, but it’s not the same as replacing a billing department.
Accuracy claims without context
Vendors frequently cite denial-reduction percentages or accuracy rates without disclosing the baseline, the payer mix, or the specialty the number came from. A tool that cuts denials by 30% at a large multi-specialty group with clean historical data may perform very differently for a small behavioral health practice with a narrower, harder-to-predict payer set.
Generic large language models presented as purpose-built
Some products are essentially a general-purpose LLM wrapped around a billing-specific prompt, with limited integration into the actual claims workflow, payer rules, or the practice’s own historical denial data. That can still be useful for drafting appeal language, but it’s a different thing than a model trained and validated on claims outcomes.
A practitioner’s view
Billing managers who’ve actually implemented these tools tend to describe the same adjustment period: the first few weeks involve more human oversight, not less, because someone has to validate that the AI’s coding suggestions and denial-risk flags match what the practice is actually seeing in its own EOBs. One RCM director at a multi-location orthopedic group put it this way in an industry interview: the tool got genuinely useful once the team stopped treating its output as a final answer and started treating it as a second set of eyes that occasionally catches something a tired biller would miss at 4 p.m. on a Friday. That’s a real improvement — it’s just a narrower one than the marketing suggests.
How to tell the difference when evaluating a tool
- Ask for denial-reduction or accuracy numbers with the underlying sample size, payer mix, and time period disclosed — not just a headline percentage.
- Ask specifically what happens when the model is uncertain: does it flag for human review, or does it make a determination on its own?
- Ask whether the model was trained/validated on data resembling your specialty and payer mix, or on a generic dataset.
- Request a reference customer of a similar size and specialty who has used the tool for at least two full quarters, not just a pilot.
- Read the contract for what data the vendor retains and how model updates are communicated — a model that changes behavior without notice can silently shift your denial patterns.
Takeaway: AI is genuinely changing specific, well-defined parts of medical billing in 2026 — claim scrubbing, denial prediction, eligibility checks, and appeal drafting chief among them — but the “fully autonomous revenue cycle” pitch remains largely marketing. Evaluate any tool on what it does with your actual claims data, not on the word “AI” in its name.